` BIT (Biotron Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

BIT
vs
S
S&P/ASX 300

Over the past 12 months, BIT has underperformed S&P/ASX 300, delivering a return of -81% compared to the S&P/ASX 300's +6% growth.

Stocks Performance
BIT vs S&P/ASX 300

Loading
BIT
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BIT vs S&P/ASX 300

Performance Gap Between BIT and AXKO
HIDDEN
Show

Performance By Year
BIT vs S&P/ASX 300

Loading
BIT
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Biotron Ltd vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Biotron Ltd
Glance View

Market Cap
6.5m AUD
Industry
Biotechnology

Biotron Ltd. operates as a clinical stage biotechnology company. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. The company is engaged in developing small molecule antiviral therapeutics targeting a range of viruses including Hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1). The firm's lead drug, BIT225 is in Phase II clinical development for the treatment of HIV-1 and HCV infections. BIT225 is a small-molecule anti-viral compound that works to inhibit the viroporin mechanism of Viral Protein U (Vpu). BIT225, in HIV-1, offers eradicate reservoirs of virus found in long-lived macrophage cells, which contribute to the need for life-long treatment with antiretroviral drugs. For HCV, BIT225 offers as a class of oral direct-acting antiviral (DAA) drug. The firm progresses its Hepatitis B virus (HBV) program. The company also designs and develops drugs drugs that target a class of viral proteins known as viroporins.

BIT Intrinsic Value
HIDDEN
Show
Back to Top